OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Tallman on the State of the Science in AML Treatment

February 17th 2017

Martin S. Tallman, MD, hematologic oncologist, chief of Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses the state of the science with regards to treatment of patients with acute myeloid leukemia (AML).

Dr. Neelapu on ZUMA-1 Trial Design of KTE-C19

February 17th 2017

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the design of the ZUMA-1 trial of the chimeric antigen receptor (CAR) T-cell therapy KTE-C19 for patients with aggressive lymphomas.

Dr. Ansell on PD-1 Inhibitors in Hodgkin Lymphoma

February 17th 2017

Stephen M. Ansell, MD, PhD, of Mayo Clinic, discusses the use of PD-1 inhibitors for patients with Hodgkin lymphoma.

Dr. Dreicer on Future Treatment Approaches in Prostate Cancer

February 17th 2017

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses the progress he would like to see accomplished in the field of metastatic castration-resistant prostate cancer.

Dr. Vokes on Different Settings in Head and Neck Cancer

February 16th 2017

Everett Vokes, MD, John E. Ultmann professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses different settings of patients with head and neck cancer.

Dr. Thompson on Advancements in Treatments of Multiple Myeloma

February 16th 2017

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses advancements of treatments for patients with multiple myeloma.

Dr. Straus on Ongoing Clinical Trials in Hodgkin Lymphoma

February 15th 2017

David J. Straus, MD, an internist and hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses ongoing clinical trials in the field of Hodgkin lymphoma.

Dr. Buffington on MRI Fusion for Prostate Cancer

February 15th 2017

Philip J. Buffington, MD, chief medical officer, The Urology Group, discusses MRI fusion-guided biopsy in patients with prostate cancer.

Rozita Yarmand on Tumor Suppressor Gene in Medullary Thyroid Cancer

February 15th 2017

Rozita Yarmand, PhD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders-Research, The University of Texas MD Anderson Cancer Center, discusses how ATF4 targets RET for degradation and is a candidate tumor suppressor gene in medullary thyroid cancer.

Dr. Terashima on Future of Bursectomy and Omentectomy for Gastric Cancer

February 15th 2017

Masanori Terashima, MD, PhD, FACS, Shizuoka Cancer Center, chairman of the Japanese Clinical Oncology Group, discusses the future of bursectomy and omentectomy for patients with gastric cancer.

Dr. Salles on Improving Immune Respone in Follicular Lymphoma

February 15th 2017

Gilles A. Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses improving immune response in follicular lymphoma.

Dr. Barcenas on Colestipol in Management of Neratinib Side Effects in HER2+ Breast Cancer

February 14th 2017

Carlos Barcenas, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses managing neratinib-related side effects with colestipol (Colestid).

Dr. Freeman on Challenges in Treatment Selection in Melanoma

February 14th 2017

Morganna Freeman, DO, associate director, Melanoma and Cutaneous Oncology Program, The Angeles Clinic and Research Institute, discusses the challenges associated with treatment selection in melanoma.

Dr. Chaudhary on Short-Term and Long-Term Future of CAR T-Cells

February 14th 2017

Preet M. Chaudhary, MD, PhD, chief of the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Department of Medicine, professor of Medicine, Ronald H. Bloom Family Chair in Lymphoma Research, and program director of the USC Norris Blood and Marrow Transplant Program, co-Leader of the Molecular Genetics Program, University of Southern California, discusses the short-term and long-term future of CAR T-cells.

Dr. Levine on Challenges in Ovarian Cancer

February 14th 2017

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses some of the ongoing challenges researchers need to tackle in the field of ovarian cancer.

Dr. Weber on Combination Strategies for BRAF-Mutant Melanoma

February 14th 2017

Jeffery S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discusses combination strategies for patients with BRAF-mutant melanoma.

Dr. Weiss on Biomarkers in Head and Neck Cancer

February 14th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses biomarkers in head and neck cancer.

Dr. Gangadhar on Combination Regimens for Melanoma

February 14th 2017

Tara C. Mitchell, MD, assistant professor of Medicine, Perelman School of Medicine at the Hospital of the University of Pennsylvania, discusses new combination regimens for patients with melanoma.

Dr. Postow on Immunotherapy Advancements in Melanoma

February 13th 2017

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the advancements that have recently taken place in immunotherapy in the field of melanoma.

Dr. Hamid on Melanoma as a Therapeutic Driver for Other Cancers

February 12th 2017

Omid A. Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses melanoma as a therapeutic driver for other tumor types during the 13th Annual 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® in Sunny Isles Beach, Florida.